Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-12-19
2009-12-29
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S078350, C424S078140, C424S078150, C424S400000, C424S486000, C514S359000
Reexamination Certificate
active
07638524
ABSTRACT:
The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
REFERENCES:
patent: 2926161 (1960-02-01), Butler et al.
patent: 3262850 (1966-07-01), Jones et al.
patent: 3288770 (1966-11-01), Butler
patent: 3369025 (1968-02-01), Bolhofer et al.
patent: 3494957 (1970-02-01), Nakanishi et al.
patent: 3607909 (1971-09-01), Boulogene et al.
patent: 3674836 (1972-07-01), Creger
patent: 3700623 (1972-10-01), Keim et al.
patent: 3716583 (1973-02-01), Nakamura et al.
patent: 3723446 (1973-03-01), Scherm et al.
patent: 3781328 (1973-12-01), Witte et al.
patent: 3833531 (1974-09-01), Keim
patent: 3840504 (1974-10-01), Keim
patent: 3948973 (1976-04-01), Phillips
patent: 3966694 (1976-06-01), Espy et al.
patent: 3971798 (1976-07-01), Humbert et al.
patent: 3983140 (1976-09-01), Endo et al.
patent: 3984413 (1976-10-01), Metz et al.
patent: 3990958 (1976-11-01), Sasse
patent: 4049813 (1977-09-01), Nadelson
patent: 4058552 (1977-11-01), Mieville
patent: 4121986 (1978-10-01), Battaerd
patent: 4167610 (1979-09-01), Bolto et al.
patent: 4230626 (1980-10-01), Chorvat
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4298715 (1981-11-01), Van Eenam
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4452957 (1984-06-01), Neigel
patent: 4483999 (1984-11-01), Thiele et al.
patent: 4604217 (1986-08-01), Lukach et al.
patent: 4659474 (1987-04-01), Perry et al.
patent: 4739073 (1988-04-01), Kathawala
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4812540 (1989-03-01), Kageno et al.
patent: 4937259 (1990-06-01), Lee
patent: 5134155 (1992-07-01), Connolly et al.
patent: 5200482 (1993-04-01), Gartner
patent: 5273995 (1993-12-01), Roth
patent: 5274155 (1993-12-01), Thottathil et al.
patent: 5316765 (1994-05-01), Folkers et al.
patent: 5428112 (1995-06-01), Ahlers et al.
patent: 5430110 (1995-07-01), Ahlers et al.
patent: 5462730 (1995-10-01), McTaggart et al.
patent: 5556619 (1996-09-01), Royce et al.
patent: 5607669 (1997-03-01), Mandeville, III et al.
patent: 5618530 (1997-04-01), Mandeville, III et al.
patent: 5624963 (1997-04-01), Mandeville, III et al.
patent: 5633344 (1997-05-01), Figuly
patent: 5679717 (1997-10-01), Mandeville, III et al.
patent: 5693675 (1997-12-01), Mandeville, III et al.
patent: 5703188 (1997-12-01), Mandeville, III et al.
patent: 5874522 (1999-02-01), Figuly et al.
patent: 6083497 (2000-07-01), Huval et al.
patent: 6203785 (2001-03-01), Holmes-Farley et al.
patent: 6248318 (2001-06-01), Huval et al.
patent: 6264938 (2001-07-01), Huval et al.
patent: 2007641 (1990-08-01), None
patent: 2016467 (1990-12-01), None
patent: 2038835 (1971-02-01), None
patent: 2149070 (1973-04-01), None
patent: 2250327 (1973-04-01), None
patent: 3122499 (1981-12-01), None
patent: 0794053 (1964-09-01), None
patent: 22478 (1981-01-01), None
patent: 33538 (1981-08-01), None
patent: 244364 (1987-11-01), None
patent: 245003 (1987-11-01), None
patent: 321090 (1989-06-01), None
patent: 329 124 (1989-08-01), None
patent: 326386 (1989-08-01), None
patent: 369323 (1990-05-01), None
patent: 0 375 350 (1990-06-01), None
patent: 380392 (1990-08-01), None
patent: 409281 (1991-01-01), None
patent: 418648 (1991-03-01), None
patent: 464845 (1992-01-01), None
patent: 0 580 078 (1994-01-01), None
patent: 0 580 079 (1994-01-01), None
patent: 0 665 245 (1995-08-01), None
patent: 860303 (1961-02-01), None
patent: 2 090 605 (1982-07-01), None
patent: 2270312 (1994-03-01), None
patent: 2 29 334 (1999-03-01), None
patent: 56-51992 (1981-05-01), None
patent: 3-109407 (1991-05-01), None
patent: 7-89898 (1995-04-01), None
patent: 8-73432 (1996-03-01), None
patent: WO 90/00897 (1990-02-01), None
patent: WO 95/34585 (1995-12-01), None
patent: WO 98/29107 (1998-07-01), None
patent: WO 98/40375 (1998-09-01), None
McCarthy, P.A., “New Approaches to Atherosclerosis: An Overview,”Medicinal Research Reviews, 13(2):139-159 (1993).
Heming, A.E. and Flanagan, T.L., “Considerations in the Selection of Cation Exchange Resins for Therapeutic Use,”In Annals of the New York Academy of Sciences, 57:239-251 (1954).
Harada, Susumu and Kunio Arai, “The Cyclo-copolymerization of Diallyl Compounds and Sulfur Dioxide, II. Diallyldimethylammonium Chloride and Sulfur Dioxide,”Die Makromolekulare Chemie107:64-77 (1967).
Negi, Youji et al., “Cyclopolymerization of Diallylamine Derivatives in Dimethyl Sulfoxide,”Journal of Polymer Science: Part A-1, 5:1951-1965 (1967).
Kuron, G.W. et al., “The Bile Acid Binding and Hypocholesterolemic Action of Two Water-soluable Polymers,”Atherosclerosis37:353-360 (1980).
Hodgkin, J.H. et al., “Use of13C-NMR in the Study of Reactions on Crosslinked Resins,”Journal of Polymer Science19(5):1239-1249 (1981).
U.S. Appl. No. 08/777,408, filed Dec. 30, 1996, “Poly (diallylamine)—Based Bile Acid Sequestrant” by Stephen Randall Holmes-Farley, Pradeep K. Dhal and John S. Petersen.
Sit, S.Y., et al., “Synthesis, Biological Profile, and Quantitative Structure-Activity Relationship of a Series of Novel 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors,”J. Med. Chem., 33(11), 2982-99 (1990).
Takano, S., et al., “Enanticonvergent Synthesis of a Promising HMG Co-A Reductase Inhibitor NK-104 from Both Enantiomers of Epichlorohydrin,”Tetrahedron:Assymetry, 4(2), 201-4 (1993).
Sood, A., et al., “Boron analogues of amino acids VI. Synthesis and characterization of di- and tripeptide analogues as antineoplastic, anti-flammatory and hypolipidemic agents,”Eur. J. Med. Chem., 25(4), 301-8 (1990).
Raulston, D.L., et al., “Inhibition of Hepatic Sterol Synthesis and Reduction of Serum Cholesterol in Rats by 5α-Cholest-8(14)-En-3β-O1-15-One,”Biochem. Biophys. Res. Commun., 71(4), 984-9 (1976).
Wint, L.T. and McCarthy,P.A., “Synthesis of Tritium Labelled (3R*,5S*) -3,5-Dihydroxy-9,9-diphenyl-6,8-nonadienoate,”J. Labelled Compd. Radiopharm., 25(11), 1289-97 (1988).
Falck, J.R. and Yang, Y-L., “Total Synthesis of (+)-Dihydromevinolin,”Tetrahedron Lett., 25(33), 3563-66 (1984).
Beck, G., et al., “Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 1.Lactones of Pyridine- and Pyrimidine- Substituted 3,5-Dihydroxy-6-heptenoic (-heptanoic) Acids,”J. Med. Chem., 33(1), 52-60 (1990).
Jendralla, H., et al., “Synthesis and Biological Activity of New HMG-CoA Reductase Inhibitors. 3.1:2Lactones of 6-Phenoxy-3,5-dihydroxyhexanoic Acids,”J. Med. Chem., 34(10) 2962-83 (1991).
Chiang, Y-C.P., et al., “Total Synthesis of L-659,699, a Novel Inhibitor of Cholesterol Biosynthesis,”J. Org. Chem., 54(24), 5708-12 (1989).
Ogawa, H., et al., “Pannorin, A New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Produced byChrysosporium pannorum,” J. Antibiot., 44(7), 762-7 (1991).
Carte, B.K., et al., “Rawsonol, An Inhibitor of HMG-CoA Reductase from the Tropical Green AlgaAvrainvillea rawsoni,” Phytochemistry, 28(11), 2917-19 (1989).
Baumann, K.L., et al., “The Convergent Synt
Dhal Pradeep K.
Holmes-Farley Stephen Randall
Huval Chad Cori
Petersen John S.
Genzyme Corporation
Hamilton Brook Smith & Reynolds P.C.
McMillian Kara R
Padmanabhan Sreeni
LandOfFree
Combination therapy for treating hypercholesterolemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for treating hypercholesterolemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for treating hypercholesterolemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149197